Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Healthy Volunteer Study to Evaluate the Impact of Various Common Interventions on Venous Pressure Signal Captured by PIVA

29 de marzo de 2021 actualizado por: Baxter Healthcare Corporation

Healthy Volunteer Study to Evaluate the Impact of Various Common Interventions on Venous Pressure Signal Captured by Peripheral Intravenous Analysis (PIVA) Technology

Non-invasive sensors have been used in research in the United States (US) to aid in the assessment of a subject's heart rate (HR), respiratory rate (RR) and fluid volume status. This estimate and its trended value over time, when used along with clinical signs and symptoms and other subject test results, can aid in the process of reaching a diagnosis and formulating a therapeutic plan when abnormalities of volume status, or RR are suspected.

Non-invasive sensors like the Peripheral IntraVenous Analysis (PIVA) sensor under development by Baxter and the Deltran blood pressure (BP) transducer, capture waveforms created by physiological mechanisms such as blood flow and breathing. An algorithm is then applied to the captured waveform to give clinicians an idea of hemodynamic (volume) status, and RR.

In this study, the functional robustness (e.g., subjects sitting, elevated leg positions, etc.) of the PIVA algorithm/technology will be demonstrated by evaluating the impact of various common interventions on the venous pressure signal. All subjects will undergo 33 interventions expected to take approximately 4 - 6 hours.

Descripción general del estudio

Estado

Terminado

Tipo de estudio

Intervencionista

Inscripción (Actual)

26

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Florida
      • Miami, Florida, Estados Unidos, 33126
        • Baxter Investigational Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 55 años (Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Has reviewed, understood and signed an informed consent.
  • Age between 18-55 years.
  • Body mass index between 18.5-35 kg/m2 with a minimum weight of 45 kg.
  • Willing and able to comply with study procedures and duration.
  • Subjects wearing any type of nail polish and/or acrylic nails must be willing to remove them prior to admission.

Exclusion Criteria:

  • Female subjects who are pregnant.
  • Subjects who are currently participating in, or have within the past 30 days participated in, another interventional clinical study or have used an investigational device or drug within the past 30 days.
  • Subjects with known respiratory conditions including but not limited to:

    • uncontrolled / severe asthma
    • flu / influenza
    • pneumonia / bronchitis
    • shortness of breath / respiratory distress
    • respiratory or lung surgery
    • emphysema, chronic obstructive pulmonary disease, lung disease
    • any other health condition that the Principal Investigator thinks can affect respiratory health
  • Subjects with self-reported heart or cardiovascular conditions including but not limited to:

    • hypertension
    • history of cardiovascular surgery
    • chest pain (angina)
    • heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia
    • previous heart attack
    • blocked artery
    • unexplained shortness of breath
    • congestive heart failure
    • history of stroke
    • transient ischemic attack
    • carotid artery disease
    • myocardial ischemia
    • myocardial infarction
    • restrictive or constrictive cardiomyopathy
    • congenital heart disease other than patent foramen ovale, repaired atrial or ventricular septal defect
    • any type of cardiac valve disease
    • history of cardiac arrhythmias
  • Self-reported health conditions as identified in the Health Assessment Form

    • diabetes
    • uncontrolled thyroid disease
    • kidney disease / chronic renal impairment
    • history of seizures (except childhood febrile seizures)
    • epilepsy
    • history of unexplained syncope
    • history of migraine attacks in the last 3 months
    • head injury within the last 2 months
    • cancer / chemotherapy
    • other known health condition should be considered upon disclosure in health assessment form
    • history of substance abuse or addiction to alcohol and or drugs within the last 12 months
  • Subjects with self-reported bleeding disorders including but not limited to:

    • hemophilia
    • von Willebrand disease
    • history of blood clots
    • history of bleeding problems
    • bruises easily with everyday activities
  • Subjects taking prescription blood thinners (like aspirin, clopidogrel, dipyridamole, or ticlopidine).
  • Subjects may be excluded at the discretion of the Investigator.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Viabilidad del dispositivo
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: IV line with an attached Deltran BP transducer
After device setup, subjects will be guided through a series of manipulations of the IV set while waveforms, pulse rate (PR), respiratory rate (RR) are collected at the start and stop of each test. At the end of the study, the PIVA algorithm will then be applied to the waveforms and calculated values will be compared with those from bedside monitors to understand the effect of common manipulations on the waveforms and determine most optimal conditions for capturing RR and PR through peripheral IV analysis.
An IV line with an attached Deltran BP transducer will be used together with LabChart software to record venous waveforms during various interventions. These waveforms will be processed using the PIVA algorithm and the calculated values will be compared to those from Nellcor respiratory monitor, Capnograph and cardiac telemetry monitoring.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Signal Quality Index (SQI) Score by Supine, Sitting, Standing Body Positions
Periodo de tiempo: End of interventions #15 (supine for 5 minutes), #17 (sitting for 5 minutes), and #19 (standing for 5 minutes)
Ranking of subject body positions (supine, sitting, standing) based upon their impact on the venous waveform signal, from best to worst, based on the PIVA algorithm-derived SQI. Score on the scale include 0=no signal, 1=poor signal, 2=good signal. The highest percentage of time with good signal quality will be the best ranked position, and the lowest percentage of time with good signal quality will be the worst ranked position.
End of interventions #15 (supine for 5 minutes), #17 (sitting for 5 minutes), and #19 (standing for 5 minutes)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Agreement between PIVA algorithm-derived RR and RR measured with Capnography at Baseline
Periodo de tiempo: End of 10 minute baseline
The difference of the PIVA algorithm-derived outcomes to their comparators (Capnography) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum. The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints. Capnography is the monitoring of the concentration or partial pressure of carbon dioxide in the respiratory gases.
End of 10 minute baseline
Agreement between PIVA algorithm-derived RR and RR measured with Nellcor bedside monitor at Baseline
Periodo de tiempo: End of 10 minute baseline
The difference of the PIVA algorithm-derived outcomes to their comparators (Nellcor) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum. The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints.
End of 10 minute baseline
Agreement between PIVA algorithm-derived RR and RR measured with manual counting
Periodo de tiempo: End of 10 minute baseline
The manual count value will be an average of the 2 minutes then the count is taken over. The difference of the PIVA algorithm-derived outcomes to their comparators (manual) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum. The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints.
End of 10 minute baseline
Agreement between PIVA algorithm derived PR and PR measured with Nellcor bedside monitor at Baseline
Periodo de tiempo: End of 10 minute baseline
The difference of the PIVA algorithm-derived outcomes to their comparators (Nellcor) under different conditions will be summarized descriptively by n, mean, median, minimum, and maximum. The 95% limit of agreement and a Bland Altman plot will also be done for these endpoints.
End of 10 minute baseline
Change in PIVA algorithm derived volume index between supine and passive leg raising positions
Periodo de tiempo: End of Interventions #15 (supine for 5 minutes) and #18 (passive leg raise for 5 minutes)
The change in PIVA algorithm-derived volume index for a change in positions will be summarized descriptively by n, mean, median, minimum, and maximum.
End of Interventions #15 (supine for 5 minutes) and #18 (passive leg raise for 5 minutes)
Change in PIVA algorithm derived volume index between supine and standing positions
Periodo de tiempo: End of interventions #15 (supine for 5 minutes) and #19 (standing for 5 minutes)
The change in PIVA algorithm-derived volume index for a change in positions will be summarized descriptively by n, mean, median, minimum, and maximum.
End of interventions #15 (supine for 5 minutes) and #19 (standing for 5 minutes)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

26 de febrero de 2020

Finalización primaria (Actual)

21 de marzo de 2020

Finalización del estudio (Actual)

21 de marzo de 2020

Fechas de registro del estudio

Enviado por primera vez

25 de marzo de 2020

Primero enviado que cumplió con los criterios de control de calidad

25 de marzo de 2020

Publicado por primera vez (Actual)

27 de marzo de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

1 de abril de 2021

Última actualización enviada que cumplió con los criterios de control de calidad

29 de marzo de 2021

Última verificación

1 de marzo de 2021

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • BXU544319
  • Pro00041143 (Otro identificador: Advarra)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

No

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir